VS-4718 (PND-1186) is a reversible and selective FAK inhibitor with IC50 of 1.5 nM. PND-1186 selectively promotes tumor cell apoptosis. Phase 1.
FAK/PYK2 inhibitors defactinib and VS-4718 enhance immune checkpoint inhibitor efficacyAlthough durable responses to single agent immune checkpoint inhibitors have been reported, additional approaches are needed to extend this therapeutic benefit to a greater proportion of cancer patients. Accordingly, ...
400 FAK Inhibitor VS-4718 Attenuates Breast Cancer Stem Cell Function and Inhibits Tumor Growth in Vivo - European Journal of Cancerdoi:10.1016/S0959-8049(12)72198-6Xu, Q.Kolev, V.N.Vidal, C.M.Shapiro, I.M.Ring, J.E.Padval, M.V....
Stephen T. KeirJohn M. MarisRichard B. LockHernan CarolMin KangC. Patrick ReynoldsJianrong WuWiley-Liss Inc.Initial testing of VS‐4718,a novel inhibitor of focal adhesion kinase (FAK),against pediatric tumor models by the pediatric preclinical testing program. Kurmasheva RT,Gorlick R,Kolb EA...